Foti RS - Search Results

1

Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials.

Foti RS, Fisher MB. Foti RS, et al. Pharmacogenomics J. 2004;4(6):362-4. doi: 10.1038/sj.tpj.6500286. Pharmacogenomics J. 2004. PMID: 15483658 Review. No abstract available.

2

Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding.

Foti RS, Fisher MB. Foti RS, et al. Drug Metab Dispos. 2004 Mar;32(3):295-304. doi: 10.1124/dmd.32.3.295. Drug Metab Dispos. 2004. PMID: 14977863

3

Assessment of UDP-glucuronosyltransferase catalyzed formation of ethyl glucuronide in human liver microsomes and recombinant UGTs.

Foti RS, Fisher MB. Foti RS, et al. Forensic Sci Int. 2005 Oct 29;153(2-3):109-16. doi: 10.1016/j.forsciint.2004.12.003. Epub 2005 Jan 15. Forensic Sci Int. 2005. PMID: 16139098

4

A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma.

Skaggs SM, Foti RS, Fisher MB. Skaggs SM, et al. Among authors: foti rs. J Pharmacol Toxicol Methods. 2006 May-Jun;53(3):284-90. doi: 10.1016/j.vascn.2005.10.002. Epub 2005 Nov 21. J Pharmacol Toxicol Methods. 2006. PMID: 16300971

5

In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance.

Strelevitz TJ, Foti RS, Fisher MB. Strelevitz TJ, et al. Among authors: foti rs. J Pharm Sci. 2006 Jun;95(6):1334-41. doi: 10.1002/jps.20538. J Pharm Sci. 2006. PMID: 16625658

6

Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance.

Fisher MB, Yoon K, Vaughn ML, Strelevitz TJ, Foti RS. Fisher MB, et al. Among authors: foti rs. Drug Metab Dispos. 2002 Oct;30(10):1087-93. doi: 10.1124/dmd.30.10.1087. Drug Metab Dispos. 2002. PMID: 12228184

7

Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment.

Engtrakul JJ, Foti RS, Strelevitz TJ, Fisher MB. Engtrakul JJ, et al. Among authors: foti rs. Drug Metab Dispos. 2005 Nov;33(11):1621-7. doi: 10.1124/dmd.105.005058. Epub 2005 Jul 27. Drug Metab Dispos. 2005. PMID: 16049128

8

Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.

Brown MF, Bahnck KB, Blumberg LC, Brissette WH, Burrell SA, Driscoll JP, Fedeles F, Fisher MB, Foti RS, Gladue RP, Guzman-Martinez A, Hayward MM, Lira PD, Lillie BM, Lu Y, Lundquist GD, McElroy EB, McGlynn MA, Paradis TJ, Poss CS, Roache JH, Shavnya A, Shepard RM, Trevena KA, Tylaska LA. Brown MF, et al. Among authors: foti rs. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3109-12. doi: 10.1016/j.bmcl.2007.03.037. Epub 2007 Mar 15. Bioorg Med Chem Lett. 2007. PMID: 17383873

9

Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates.

Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS, Rock DA. Pearson JT, et al. Among authors: foti rs. Chem Res Toxicol. 2007 Dec;20(12):1778-86. doi: 10.1021/tx700207u. Epub 2007 Nov 15. Chem Res Toxicol. 2007. PMID: 18001057

10

Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.

Foti RS, Rock DA, Pearson JT, Wahlstrom JL, Wienkers LC. Foti RS, et al. Drug Metab Dispos. 2011 Jul;39(7):1188-95. doi: 10.1124/dmd.111.038505. Epub 2011 Mar 29. Drug Metab Dispos. 2011. PMID: 21447734

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters